Roche Halts Two Huntington’s Gene-Silencing Programs After Interim Data Miss Efficacy Thresholds

{"The decision follows earlier termination of the phase 3 tominersen trial in 2021, where high-dose regimens paradoxically accelerated decline. Current programs targeted different HTT transcript regions yet produced comparable null results on motor and cognitive endpoints at 18 months, prompting Roche to reallocate resources away from HTT-lowering modalities.","This pattern mirrors setbacks at Wave Life Sciences and Ionis/Biogen, where allele-selective and non-selective ASOs alike failed to translate biomarker reductions into functional benefit. The repeated dissociation between CSF mutant huntingtin lowering and clinical scores suggests that cortical and striatal delivery, timing of intervention, or downstream protein clearance may be rate-limiting factors not captured in rodent models.","ARPA-H’s new $160 million bespoke gene-editing initiative highlights the policy response to such volatility, yet regulatory precedents from the 2024 FDA rejection of another HTT-targeted therapy indicate that surrogate endpoints alone will not suffice for accelerated approval. Observational natural-history cohorts remain essential to define minimal clinically important differences.","Next steps require longer-duration trials with prespecified subgroup analyses by CAG repeat length and disease stage, plus integration of digital biomarkers to detect slower trajectories that standard scales miss."}